Nektar
-
AstraZeneca and Nektar Ink Agreement for Constipation Drug
AstraZeneca and Nektar Therapeutics have entered into an exclusive worldwide license agreement for two drug development programmes: NKTR-118, a late stage investigational product that is being evaluated for the treatment of opioid-induced constipatio…
Nektar | 24 September 2009
-
Novartis to acquire Nektar Therapeutics pulmonary business unit
Novartis has strengthened its capabilities for developing medicines that can be delivered via the lungs through a definitive agreement to acquire the pulmonary drug delivery business unit of Nektar Therapeutics for $115 million in cash. Important…
Nektar | 28 October 2008
